Affect Therapeutics uses mobile technology to revolutionize stimulant addiction recovery.
Affect Therapeutics has raised $16.0M in total funding. The most recent round was Series A. The last funding was announced in July 2023.
Affect Therapeutics's investors include Samsung NEXT, Kapor Capital, AlleyCorp, Artis Ventures, What If Ventures.
Affect Therapeutics is headquartered in New York, United States.
Affect Therapeutics uses mobile technology to revolutionize stimulant addiction recovery.
Affect Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Affect Therapeutics — Funding & Investors." VCBacked, July 12, 2023, https://www.vcbacked.co/company/affect-therapeutics. Accessed July 20, 2026.
VCBacked. (2023). Affect Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/affect-therapeutics
{{cite web |title=Affect Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/affect-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated